AI assistant
CONTROL BIONICS LIMITED — Regulatory Filings 2021
Apr 5, 2021
64611_rns_2021-04-05_fe4a767f-e71c-41b6-9201-ab6b0108fbab.pdf
Regulatory Filings
Open in viewerOpens in your device viewer
==> picture [102 x 36] intentionally omitted <==
6 April 2021
ASX ANNOUNCEMENT
Release of shares from escrow
Control Bionics Ltd (ASX: CBL) announces that in accordance with listing rule 3.10A, a total of 6,579 ordinary fully paid shares will be released from mandatory escrow on 16 April 2021.
The Company will apply to the ASX for quotation of the ordinary shares upon release from escrow.
This announcement was authorised by the CEO, Rob Wong.
Investors
Brett Crowley - Company Secretary [email protected]
Business/Client Inquiries Rob Wong - CEO [email protected]
Media
M&C Partners Melissa Hamilton [email protected]
For further information visit the website: https://www.controlbionics.com/
About Control Bionics:
Control Bionics is a technology company which enables a disabled person to use their own neuroelectric signals, from their brain to a muscle, to control communication and movement through smartphones, tablets, computers and robotics, even when that muscle is not fully functional. The Company’s wireless wearable device, ‘ NeuroNode ’, is a world leader in electromyography (EMG), capturing and processing those neuroelectric signals into electronic commands to do everything they would normally do with a keyboard, mouse, joystick or touchscreen. The technology also enables a person to use their eyes to replace a mouse in controlling a cursor on a screen simply by looking where they want to cursor to move; and then to select anything under the cursor, using NeuroNode; providing fast, intuitive communication and control through text, text-to-speech, emails, phone-messaging, web surfing and robotics.
Control Bionics Limited
Registered Office: Level 5, 23-25 O’Connell Street, Sydney, NSW, 2000 T: +61 3 9897 3576 W: www.controlbionics.com
ABN: 45 115 465 462